Skip to main content

Table 7 Relationship between BRCA1/2 methylation and clinicopathological variables in BRCA1-related carcinomas

From: BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers

BRCA1-related carcinomas Grades 1–2 vs. 3 Ductal vs. lobular tumors ER-positive vs. ER-negative PR-positive vs. PR-negative HER2-positive vs. HER2-negative
Probe Test statistica p Value Test statistica p Value Test statistica p Value Test statistica p Value Test statistica p Value
BRCA1.1 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
BRCA1.2 0.145b 0.653 1.262b 0.356 0.087b 1.000 0.038b 1.000 0.225b 1.000
BRCA1.3 0.031b 1.000 0.342b 1.000 0.115b 1.000 0.096b 1.000 0.151b 1.000
BRCA1 totalc 0.145b 0.653 1.262b 0.356 0.087b 1.000 0.038b 1.000 0.225b 1.000
BRCA2.1 0.005b 1.000 1.694b 0.310 0.000b 1.000 0.363b 0.669 0.308b 1.000
BRCA2.2 0.009b 1.000 0.265b 1.000 3.482b 0.099 0.001b 1.000 0.117b 1.000
BRCA2.3 0.003b 1.000 3.328b 0.144 0.209bb 0.740 0.070b 1.000 0.793b 1.000
BRCA2.4 0.975b 1.000 0.193b 1.000 1.625b 0.253 1.121b 0.556 0.086b 1.000
BRCA2 totalc 0.005b 1.000 1.694b 0.310 0.000b 1.000 0.363b 0.669 0.308b 1.000
  1. Abbreviations: BRCA1/2 BRCA1 and BRCA2, ER Estrogen receptor, HER2 Human epidermal growth factor receptor 2, N/A Not applicable, because one of the two variables (either the methylation probe or the clinicopathological variable) was a constant, PR Progesterone receptor
  2. aPearson’s chi-square test or Fisher’s exact test
  3. bFisher’s exact test
  4. cPearson’s chi-square test